New treatments have changed the face of managing hemophilia with an inhibitor, columnist Cazandra Campos-MacDonald writes.

Preventive treatment (prophylaxis) has relied on factor VIII products given through frequent injection. Newer treatments include gene therapy; Hemlibra (emicizumab), which can be given through ...

Newer treatments include gene therapy; Hemlibra (emicizumab), which can be given through outpatient care every few weeks; and drugs still in clinical trials such as fitusiran. There are two types ...

Biologics are also used in hematologic conditions such as hemophilia A and B. Factor replacement therapies and newer agents like emicizumab (Hemlibra) are used to reduce bleeding episodes. In patients ...

Emicizumab-kxwh (Hemlibra) is the first FDA-approved non–factor replacement therapy for hemophilia A. 34,38 It is approved for routine prophylaxis to prevent or decrease the frequency of ...

The launch of Hemlibra (emicizumab) in 2017, with a label expansion in 2018 to broaden its use – had a speedy impact on Eloctate, which also came from Bioverativ's stable. Sanofi recorded a $2 ...

Emicizumab is a relatively new hemophilia therapy that has been shown to substantially increase bleeding protection. Hemophilia is a bleeding disorder that can often cause long-term joint damage and ...

and Hemlibra (emicizumab) for haemophilia. Diagnostic led the charge, rising 24% to CHF 5.3 billion, but pharma also had a solid start to the year with a 6% gain to CHF 11.2 billion. Ocrevus rose ...